Esperion Therapeutics (ESPR) Assets Average (2013 - 2026)

Esperion Therapeutics has reported Assets Average for 14 years, with the latest figure at $464.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 39.02% year-over-year to $464.2 million; the trailing twelve-month figure through Mar 2026 stood at $464.2 million (up 39.02% YoY), and the FY2025 full-year result was $404.9 million, up 47.32% from the prior year.
• Assets Average for Q1 2026 stood at $464.2 million, up from $415.0 million in the prior quarter.
• The five-year high for Assets Average was $464.2 million in Q1 2026, with the low at $213.6 million in Q4 2023.
• Historically, Assets Average has averaged $319.3 million across 5 years, with a median of $329.0 million in 2024.
• Annual changes were most pronounced in 2023 — Assets Average sank 31.01% — and 2024, when it soared 54.05%.
• Esperion Therapeutics' Assets Average stood at $280.4 million in 2022, then dropped by 23.84% to $213.6 million in 2023, then soared by 54.05% to $329.0 million in 2024, then climbed by 26.14% to $415.0 million in 2025, then gained by 11.87% to $464.2 million in 2026.
• The last three Assets Average figures came in at $464.2 million (Q1 2026), $415.0 million (Q4 2025), and $355.6 million (Q3 2025), per Business Quant data.